We are live on ! Find out more
WHWK

Whitehawk Therapeutics
WHWK

40 hedge funds and large institutions have $19.4M invested in Whitehawk Therapeutics in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

21% more funds holding

Funds holding: 33 → 40 (+7)

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

0.03% more ownership

Funds ownership: 2.76% → 2.8% (+0.03%)

26% less capital invested

Capital invested by funds: $26.1M → $19.4M (-$6.71M)

Holders
40
Holders Change
+7
Holders Change %
+21.21%
% of All Funds
0.71%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
12
Increased
10
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.19M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$469K
3
Renaissance Technologies
Renaissance Technologies
New York
+$447K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$356K
5
VF
Virtu Financial
New York
+$191K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$4.94M
2
Citadel Advisors
Citadel Advisors
Florida
-$2.81M
3
BFM
Boothbay Fund Management
New York
-$521K
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$266K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$241K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Alerce Investment Management
Illinois
$5.51M +$8.01M +374,789 New
O
2
OrbiMed
New York
$5.09M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.66M +$2.19M +102,355 +131%
Renaissance Technologies
4
Renaissance Technologies
New York
$1.76M +$447K +20,924 +21%
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$1.48M +$469K +21,912 +28%
IC
6
Ikarian Capital
Texas
$468K -$4.94M -231,112 -88%
AICPI
7
ABG Innovation Capital Partners III
Hong Kong
$392K +$570K +26,667 New
JIC
8
Johnson Investment Counsel
Ohio
$314K – – –
PHP
9
Parkman Healthcare Partners
Connecticut
$259K -$50.8K -2,375 -12%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$245K +$356K +16,667 New
VF
11
Virtu Financial
New York
$168K +$191K +8,943 +363%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$148K +$42.2K +1,973 +24%
BlackRock
13
BlackRock
New York
$116K +$5.82K +272 +4%
NRS
14
Neville Rodie & Shaw
New York
$98K – – –
Ameriprise
15
Ameriprise
Minnesota
$82K -$162K -7,568 -58%
Citadel Advisors
16
Citadel Advisors
Florida
$80K -$2.81M -131,262 -96%
Qube Research & Technologies (QRT)
17
Qube Research & Technologies (QRT)
United Kingdom
$67K -$266K -12,452 -73%
Northern Trust
18
Northern Trust
Illinois
$54K -$1.35K -63 -2%
BFM
19
Boothbay Fund Management
New York
$49K -$521K -24,382 -88%
US Bancorp
20
US Bancorp
Minnesota
$49K – – –
PAM
21
Panagora Asset Management
Massachusetts
$44K +$63.6K +2,975 New
Arrowstreet Capital
22
Arrowstreet Capital
Massachusetts
$35K – – –
Morgan Stanley
23
Morgan Stanley
New York
$25K +$35.7K +1,671 New
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$24K +$34.4K +1,607 New
UBS Group
25
UBS Group
Switzerland
$21K +$30.8K +1,441 +11,085%
1
2

WHWK Hedge Fund Activity: Q4 2020 in Review

40 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2020, worth a combined $19.4M — down 26% from $26.1M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new WHWK positions and 5 closed out — a net gain of 7 holders — while 10 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.19M. The largest seller was Ikarian Capital, cutting an estimated $4.94M.

  • 40 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2020, up from 33 in Q3 2020.
  • Funds reported $19.4M of Whitehawk Therapeutics stock for Q4 2020, down 26% quarter-over-quarter.
  • 12 funds opened new Whitehawk Therapeutics positions in Q4 2020 and 5 closed out, a net change of +7 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $2.19M added.
  • The largest Whitehawk Therapeutics seller in Q4 2020 was Ikarian Capital, an estimated $4.94M sold.

Based on aggregated 13F filings for Q4 2020.